Pharmacogenomics: The Promising Future of Clinical Therapeutics

被引:0
|
作者
Arafah, Azher [1 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh 11451, Saudi Arabia
关键词
pharmacogenetics; pharmacogenomics; adverse drug reaction; drug transporters; gene variants; precision medicine; IMPLEMENTATION CONSORTIUM GUIDELINES; DRUG-METABOLIZING-ENZYMES; PERSONALIZED MEDICINE; BREAST-CANCER; GENETIC-CONTROL; CYP2C19; GENOTYPE; TRANSPORTER; ASSOCIATION; RESISTANCE; WARFARIN;
D O I
10.23812/j.biol.regul.homeost.agents.20243803.144
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pharmacogenomics (PGx), a rapidly evolving field at the intersection of pharmacology and genomics, has the potential to revolutionize medical practice by investigating how an individual's genetic makeup influences their response to drugs. By optimizing drug selection, dosage, and treatment strategies based on an individual's genetic profile, pharmacogenomics aims to improve therapeutic outcomes, minimize adverse reactions, and enhance healthcare efficiency. Recent advancements in high-throughput genotyping technologies and the availability of genomic data have paved the way for personalized and targeted therapies. This review highlights pharmacogenomics's fundamental principles, applications, and challenges, emphasizing its potential to transform clinical practice and patient care. The field has made significant progress in understanding the impact of genetic variants on drug response, ranging from monogenic to complex polygenic variants. However, the implementation of pharmacogenomics in public health institutions remains limited. With continuous advancements and increasing integration of genomics into medicine, pharmacogenomics is poised to play a crucial role in precision medicine, improving drug efficacy, minimizing toxicity, and driving advancements in drug discovery and development.
引用
收藏
页码:1809 / 1829
页数:21
相关论文
共 50 条
  • [31] Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics
    Chavda, Vishal
    Vashi, Ruju
    Patel, Snehal
    CURRENT DRUG TARGETS, 2021, 22 (14) : 1629 - 1636
  • [32] Pharmacogenomics: Translating functional genomics into rational therapeutics
    Evans, WE
    Relling, MV
    SCIENCE, 1999, 286 (5439) : 487 - 491
  • [33] Flavonoids as promising anticancer therapeutics: Contemporary research, nanoantioxidant potential, and future scope
    Gupta, Mukta
    Ahmad, Javed
    Ahamad, Javed
    Kundu, Snehashis
    Goel, Archit
    Mishra, Awanish
    PHYTOTHERAPY RESEARCH, 2023, 37 (11) : 5159 - 5192
  • [34] The future of psychiatric pharmacogenomics
    Lohoff, Falk W.
    PHARMACOGENOMICS, 2011, 12 (07) : 927 - 929
  • [35] Pharmacogenomics: Translating functional genomics into rationale therapeutics
    Evans, WE
    FASEB JOURNAL, 2000, 14 (08): : A1307 - A1307
  • [36] The future of thiopurine pharmacogenomics
    Duley, John A.
    Somogyi, Andrew A.
    Martin, Jennifer H.
    PHARMACOGENOMICS, 2012, 13 (14) : 1549 - 1552
  • [37] Colorectal cancer therapeutics and the challenges of applied pharmacogenomics
    Kruzelock, Russell P.
    Short, William
    CURRENT PROBLEMS IN CANCER, 2007, 31 (05) : 315 - 366
  • [38] Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: The way forward
    Terra S.G.
    Johnson J.A.
    American Journal of Cardiovascular Drugs, 2002, 2 (5) : 287 - 296
  • [39] Pharmacogenomics revolutionizing cardiovascular therapeutics: A narrative review
    Inshutiyimana, Samuel
    Ramadan, Nagham
    Razzak, Rawane Abdul
    Al Maaz, Zeina
    Wojtara, Magda
    Uwishema, Olivier
    HEALTH SCIENCE REPORTS, 2024, 7 (10)
  • [40] Pharmacogenomics: Challenges and Future
    Arbitrio, Mariamena
    GENES, 2024, 15 (06)